A recently published article in the American Journal of Public Health has attributed a substantial financial cost to untreated perinatal mood and anxiety disorders among mothers. The study, conducted by researchers with the think [...]
Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on the practice of reproductive psychiatry amidst the COVID-19 pandemic with Ob.Gyn News on [...]
Zuranolone or SAGE-217 is similar to brexanolone (marketed as Zulresso), the medication which was FDA-approved for the treatment of postpartum depression. Zuranolone is a neurosteroid, an analogue of allopregnanolone, which is a positive allosteric [...]
Interpersonal therapy (IPT) has been shown to be effective for the treatment of postpartum depression. Typically this treatment is delivered in person; however given limited access to specialized providers, recent research has explored the [...]
Transcranial magnetic stimulation (TMS), an FDA approved treatment for major depression, is a noninvasive procedure which uses magnetic fields to stimulate specific areas of the brain. It is not commonly used as a first [...]
It is great to see so many well-written and researched reports on perinatal depression in the news these days. Here are a few great stories from NPR published over the last couple of months. [...]
Programs are necessary to implements strategies for reducing the risk of suicide and infanticide in postpartum women, especially in women at risk for postpartum psychosis.Â
In the United States, about one out of every 160 pregnancies ends in stillbirth, defined as a pregnancy loss occurring after 20 weeks’ gestation. Perinatal loss is a traumatic event for women and their [...]
Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on diagnosing and treating postpartum psychosis with Ob.Gyn News on January 30th, 2020 Although [...]
While we have been talking about using brexanolone, marketed by Sage Therapeutics as Zulresso, for the treatment of postpartum depression, an oral version of this novel antidepressant - SAGE 217 or zuranolone - has [...]
